Efficacy of fibrinogen/thrombin [VeraSeal] in patients undergoing vascular surgery

Trial Profile

Efficacy of fibrinogen/thrombin [VeraSeal] in patients undergoing vascular surgery

Completed
Phase of Trial: Phase III

Latest Information Update: 03 Nov 2015

At a glance

  • Drugs Fibrinogen/thrombin (Primary)
  • Indications Surgical blood loss
  • Focus Therapeutic Use
  • Most Recent Events

    • 03 Nov 2015 New trial record
    • 28 Sep 2015 According to a European Medicines Agency media release, Grifols announced the withdrawal of its MAA of VeraSeal intended to control surgical blood loss during vascular surgery.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top